PureTech Health plc

NASDAQ:PRTC

Biotechnology

Healthcare
$17.38 +2.64%

+$0.45 today

Market cap
$423.09M
Beta
0.79
P/E (TTM)
-0.4
EPS (TTM)
-$45.37
52W Low $14.50High $19.92

Volume 0.01M

Average 0.01M

PRTC Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

PureTech Health plcNASDAQ: PRTC

Gross Margin · Q4 FY2025 · quarter ended Dec 2025

Gross margin narrows to 41.0%

Gross margin was 41.0% in Q4 FY2025, down 1025.6 pp from a year earlier. Over 3 fiscal years it widened by 6646.2 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
41.0%— QoQ
Last fiscal yearDec 2025
100.0%+74.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1025.6 pp——
1 year+74.0 pp——
3 years+6646.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+74.0pp

Gross Margin vs competitors

How PRTC compares with its peers on the latest reported figures

  • PRTC's FY2025 gross margin of 100.0% is the highest of the 6 companies compared; the peer median is 88.2%.
  • Its year-over-year change of +74.0 pp is the 2nd highest of 6, against a peer median of -2.0 pp.
  • Over three fiscal years its change of +6646.2 pp compares with a peer median of -7.9 pp.
PRTC Competitors Peer median
Gross Margin for PRTC and competitors
Company Period LTM level YoY 3-year change
PRTCPureTech Health plcFY2025100.0% +74.0 pp+6646.2 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
ALMSAlumis Inc. Common StockLTM Jun 202688.2% -7.7 pp—
QSIQuantum-Si incorporatedLTM Mar 202640.0% -12.8 pp—
AUTLAutolus Therapeutics plcLTM Mar 2026-11.2% +1636.4 pp-127.8 pp
SLDBSolid Biosciences Inc.FY2025— ——
NGNENeurogene Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding PRTC) 88.2%-2.0 pp-7.9 pp

Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.98M2.09M3.33M4.83M4.66M
Cost of Revenue110.47M152.43M4.93M3.57M3.36M
Gross Profit(100.49M)(136.82M)(1.6M)1.26M4.66M
Gross Margin-1007.0%-6546.2%-48.1%26.0%100.0%
Research & Development81.52M116.11M96.24M54.28M45.74M
Selling, General & Admin30.76M35.67M48.36M27.49M20.65M
Operating Expenses160.26M60.99M54.55M140.41M103.18M
Depreciation & Amortization7.24M8.89M4.93M3.57M3.35M
EBITDA26.7M(188.91M)(11.63M)37.38M(61.8M)
EBITDA Margin267.6%-9038.9%-349.2%774.3%-1326.5%
Operating Income(150.28M)(197.81M)(146.2M)(136.1M)(98.53M)
Operating Margin-1506.0%-9464.4%-4390.4%-2818.9%-2114.7%
Interest Income214K5.8M16.01M22.67M13.05M
Interest Expense4.71M3.95M13.49M10.04M45.78M
Other Income / Expenses91.33M105.02M110.1M159.87M(12.4M)
Income Before Tax(58.95M)(92.78M)(36.1M)23.77M(110.93M)
Pre-Tax Margin-590.8%-4439.4%-1084.2%492.4%-2380.9%
Income Tax Expense3.76M(55.72M)30.53M(4.01M)(842K)
Net Income(60.56M)(50.36M)(65.7M)53.51M(109.74M)
Net Margin-606.9%-2409.3%-1972.9%1108.3%-2355.4%
EPS (Basic)(2.10)(1.80)(2.40)2.00(46.00)
EPS (Diluted)(2.10)(1.80)(2.40)2.00(46.00)
Weighted Avg Shares28.66M27.97M27.63M26.97M2.41M
Weighted Avg Shares (Diluted)28.66M28.48M27.63M26.97M2.41M

PureTech Health plc

NASDAQ:PRTC

Intrinsic Alpha fair value

Locked

Current Price

$17.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.